[2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]butyric acid | 1279843-80-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]butyric acid
• 英文别名: 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-ylmethoxy]butyric acid；2-[[5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]methoxy]butanoic acid；2-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazol-3-yl]methoxy]butanoic acid
• CAS: 1279843-80-9
• 化学式: C₂₁H₁₉Cl₃N₂O₃
• 分子量: 453.752
• InChiKey: JCESIDARNZWWMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,4-二氯苯肼盐酸盐 在 甲醇 、 lithium aluminium tetrahydride 、 sodium hydride 、 溶剂黄146 、 三乙胺 、 potassium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 48.75h， 生成 [2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl]methoxy]butyric acid
  参考文献：
  名称：

  Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold

  摘要：

  The CB1 receptor belongs to the G-protein-coupled receptor superfamily. CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In this study, we report the synthesis and in vitro binding affinity assay of some 1,5-diarylpyrazole scaffold compounds. The binding results showed that some of the target compounds had an excellent potency toward the CB1 receptor with IC(50) values lying at the nanomole level.

  DOI：

  10.3109/14756366.2010.491794

文献信息

• [EN] PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS<br/>[FR] DÉRIVÉS DE PYRAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DE LPAR5
  申请人：SANOFI SA

  公开号：WO2013171317A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of the formula (I), wherein theresidues R1 to R5, V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in thetreatmentof diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及公式（I）的化合物，其中残基R1至R5、V、G和M具有所述权利要求中指示的含义。公式（I）的化合物是有价值的药理活性化合物，可用于治疗各种疾病，例如心血管疾病，如血栓栓塞病或再狭窄。本发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可应用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活情况或预防或治愈需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。本发明还涉及制备公式（I）化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• Pyrazole Derivatives And Their Use As LPAR5 Antagonists
  申请人：SANOFI

  公开号：US20150141477A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of the formula (I), wherein the residues R 1 to R 5 , V, G and M have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及式(I)化合物，其中残基R1至R5、V、G和M具有所述权利要求中指示的含义。式(I)化合物是有价值的药理活性化合物，可用于治疗多种疾病，例如心血管疾病，如血栓栓塞疾病或再狭窄。本发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可应用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活情况或治疗或预防需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。本发明还涉及制备式(I)化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• PYRAZOLE DERIVATIVES AND THEIR USE AS LPAR5 ANTAGONISTS
  申请人：SANOFI

  公开号：EP2882715A1

  公开（公告）日：2015-06-17
• US9346762B2
  申请人：——

  公开号：US9346762B2

  公开（公告）日：2016-05-24
• Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold
  作者：GuoGang Tu、Fang Xiong、HuiMing Huang、BinHai Kuang、ShaoHua Li

  DOI：10.3109/14756366.2010.491794

  日期：2011.4.1

  The CB1 receptor belongs to the G-protein-coupled receptor superfamily. CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In this study, we report the synthesis and in vitro binding affinity assay of some 1,5-diarylpyrazole scaffold compounds. The binding results showed that some of the target compounds had an excellent potency toward the CB1 receptor with IC(50) values lying at the nanomole level.